Bruce Cozadd, who co-founded the company two decades ago, will step down once a successor is found. Jazz aims to complete its ...

Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal.

MaaT Pharma is at the forefront of innovation in this field, striving to achieve the first-ever approval of a ...

The biotech company will meet with regulators to discuss Phase 2 biomarker data that sent its shares climbing by more than 20 ...

Novo Nordisk is investing more than $1 billion in a new production facility in Denmark. Elsewhere, drugs from Neurocrine ...

The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...

The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...